UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

Journal of clinical oncology, 2015-03, Vol.33 (8), p.910-915

2015

Volltextzugriff (PDF)

Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma

Journal of clinical oncology, 2006-03, Vol.24 (9), p.1443-1448

2006

Volltextzugriff (PDF)

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2014-09, Vol.20 (17), p.4647-4659

2014

Volltextzugriff (PDF)

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2019-06, Vol.24 (6), p.e251-e259

2019

Volltextzugriff (PDF)

Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

Clinical lung cancer, 2014-03, Vol.15 (2), p.166-170

2014

Volltextzugriff (PDF)

Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma

European journal of cardio-thoracic surgery, 2013-07, Vol.44 (1), p.104-110

2013

Volltextzugriff (PDF)

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric Phase II study

Cancer, 2003-06, Vol.97 (11), p.2791-2797

2003

Volltextzugriff (PDF)

Second and third line treatment in advanced non-small cell lung cancer

Discovery medicine, 2009-12, Vol.8 (43), p.204-209

2009

Volltextzugriff (PDF)

Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network during the first and second pandemic waves

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.6511-6511

2021

Volltextzugriff (PDF)

Clinicopathological features of patients with malignant mesothelioma in a multicenter, retrospective study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e12651-e12651

2015

Volltextzugriff (PDF)

Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7501-7501

2015

Volltextzugriff (PDF)

Stanford V Regimen plus Consolidative Radiotherapy Is an Effective Therapeutic Program for Bulky or Advanced-Stage Hodgkin’s Disease

Acta haematologica, 2004-01, Vol.112 (3), p.141-147

2004

Volltextzugriff (PDF)

Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7527-7527

2014

Volltextzugriff (PDF)

Clinicopathologic features of patients with malignant mesothelioma in a multicenter, retrospective study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e18544-e18544

2014

Volltextzugriff (PDF)

A multicenter, randomised, phase III trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in advanced SCLC patients. The STAD-1 trial

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7505-7505

2015

Volltextzugriff (PDF)

Non-platinum combination of gemcitabine in NSCLC

Annals of oncology, 2006-05, Vol.17 (suppl-5), p.v82-v85

Favaretto, A.G.

2006

Volltextzugriff (PDF)

Prospective randomized phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) patients (pts) with nonsquamous (non SCC) histologic type: NAVoTRIAL01—Preliminary results

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7575-7575

2012

Volltextzugriff (PDF)

The predictive role of integrated BRCA1 and HERC2 mRNA expression in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based first-line chemotherapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.11078-11078

2013

Volltextzugriff (PDF)

The role of cisplatin (CDDP) or carboplatin (CARBO) plus pemetrexed (PEM) in nonsquamous (NON-SQM) non-small cell lung cancer (NSCLC): Results of an Italian retrospective multicentric study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e19072-e19072

2014

Volltextzugriff (PDF)

NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8036-8036

2014

Volltextzugriff (PDF)

DNA repair components modulating the function of breast cancer susceptibility gene 1 ( BRCA1 ) in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based chemotherapy

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e18130-e18130

2012

Volltextzugriff (PDF)

Malignant pleural mesothelioma (MPM) in elderly patients: A multicenter survey

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7082-7082

2012

Volltextzugriff (PDF)

Prospective randomised phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) with nonsquamous (Non SCC) histological type. NAVoTRIAL01: Final results

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8043-8043

2013

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(25)
Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Female
(23)
Male
(22)
Aged
(21)
Oncology
(21)
Middle Aged
(18)
Adult
(16)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Lung Neoplasms - Drug Therapy
(14)
Treatment Outcome
(11)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(10)
Biological And Medical Sciences
(10)
Chemotherapy
(10)
Medical Sciences
(10)
Aged, 80 And Over
(9)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Prognosis
(9)
Deoxycytidine - Analogs & Derivatives
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non‐Small Cell Lung Cancer

Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric Phase II study

Second and third line treatment in advanced non-small cell lung cancer

Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network during the first and second pandemic waves

A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for EGFR mt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatment with erlotinib

Clinicopathological features of patients with malignant mesothelioma in a multicenter, retrospective study

Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)

Stanford V Regimen plus Consolidative Radiotherapy Is an Effective Therapeutic Program for Bulky or Advanced-Stage Hodgkin’s Disease

Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy

Clinicopathologic features of patients with malignant mesothelioma in a multicenter, retrospective study

A multicenter, randomised, phase III trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in advanced SCLC patients. The STAD-1 trial

Non-platinum combination of gemcitabine in NSCLC

Prospective randomized phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) patients (pts) with nonsquamous (non SCC) histologic type: NAVoTRIAL01—Preliminary results

The predictive role of integrated BRCA1 and HERC2 mRNA expression in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based first-line chemotherapy

The role of cisplatin (CDDP) or carboplatin (CARBO) plus pemetrexed (PEM) in nonsquamous (NON-SQM) non-small cell lung cancer (NSCLC): Results of an Italian retrospective multicentric study

NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI

DNA repair components modulating the function of breast cancer susceptibility gene 1 ( BRCA1 ) in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based chemotherapy

Malignant pleural mesothelioma (MPM) in elderly patients: A multicenter survey

Prospective randomised phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) with nonsquamous (Non SCC) histological type. NAVoTRIAL01: Final results

Suchergebnisse filtern